Zevra Therapeutics (ZVRA) Financials

$8.65 +0.08 (+0.93%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$8.62 -0.03 (-0.36%)

As of 05/23/2025 07:50 PM Eastern

Annual Income Statements for Zevra Therapeutics

This table shows Zevra Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-106	-46	-27
Consolidated Net Income / (Loss)	-106	-46	-27
Net Income / (Loss) Continuing Operations	-106	-46	-27
Total Pre-Tax Income	-90	-46	-27
Total Operating Income	-87	-50	-43
Total Gross Profit	16	25	9.94
Total Revenue	24	27	10
Operating Revenue	24	27	10
Total Cost of Revenue	7.42	2.17	0.22
Operating Cost of Revenue	7.42	2.17	0.22
Total Operating Expenses	103	75	53
Selling, General & Admin Expense	55	34	15
Research & Development Expense	42	40	37
Amortization Expense	6.24	0.77	-
Total Other Income / (Expense), net	-3.14	3.56	16
Interest Expense	5.18	-3.04	-1.18
Other Income / (Expense), net	2.04	0.52	15
Income Tax Expense	15	0.00	-0.03
Basic Earnings per Share	($2.28)	($1.30)	($0.78)
Weighted Average Basic Shares Outstanding	46.25M	35.45M	34.49M
Weighted Average Diluted Shares Outstanding	54.12M	43.43M	34.54M
Weighted Average Basic & Diluted Shares Outstanding	54.12M	43.43M	34.54M

This table shows Zevra Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-36	-33	-20	-17	-20	-10	-2.57	-13	5.75	-6.62
Consolidated Net Income / (Loss)	-36	-33	-20	-17	-20	-10	-2.57	-13	5.75	-6.62
Net Income / (Loss) Continuing Operations	-36	-33	-20	-17	-20	-10	-2.57	-13	5.75	-6.62
Total Pre-Tax Income	-20	-33	-20	-17	-20	-10	-2.65	-13	6.47	-6.65
Total Operating Income	-15	-27	-24	-20	-15	-15	-6.25	-13	-9.31	-6.63
Total Gross Profit	11	1.39	0.88	3.25	12	2.75	7.79	3.05	2.00	2.73
Total Revenue	12	3.70	4.45	3.43	13	2.90	8.47	3.18	2.02	2.87
Operating Revenue	12	3.70	4.45	3.43	13	2.90	8.47	3.18	2.02	2.87
Total Cost of Revenue	1.37	2.30	3.57	0.18	1.23	0.14	0.68	0.13	0.02	0.14
Operating Cost of Revenue	1.37	2.30	3.57	0.18	1.23	0.14	0.68	0.13	0.02	0.14
Total Operating Expenses	26	29	25	24	27	18	14	16	11	9.36
Selling, General & Admin Expense	16	16	13	9.93	15	5.82	6.61	7.23	4.77	3.97
Research & Development Expense	8.35	11	11	12	11	12	7.43	8.66	6.54	5.39
Amortization Expense	1.62	1.55	1.55	1.53	0.77	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	-4.95	-5.92	3.94	3.79	-4.74	5.17	3.61	-0.49	16	-0.02
Interest Expense	2.27	1.26	1.84	-0.19	0.55	-1.37	-1.36	-0.86	-0.65	-0.09
Other Income / (Expense), net	-2.69	-4.66	5.78	3.60	-4.19	3.80	2.25	-1.35	15	-0.12
Income Tax Expense	15	0.00	0.07	-0.07	-	0.18	-0.07	-0.10	0.72	-0.03
Basic Earnings per Share	($0.71)	($0.69)	($0.48)	($0.40)	($0.54)	($0.30)	($0.08)	($0.38)	$0.16	($0.19)
Weighted Average Basic Shares Outstanding	46.25M	47.81M	41.90M	41.78M	35.45M	34.72M	33.90M	34.47M	34.49M	34.49M
Weighted Average Diluted Shares Outstanding	54.12M	53.38M	52.62M	41.85M	43.43M	36.22M	33.93M	33.88M	34.54M	34.50M
Weighted Average Basic & Diluted Shares Outstanding	54.12M	53.38M	52.62M	41.85M	43.43M	36.22M	33.93M	33.88M	34.54M	34.50M

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-9.26	-22	-47
Net Cash From Operating Activities	-70	-34	-19
Net Cash From Continuing Operating Activities	-70	-34	-19
Net Income / (Loss) Continuing Operations	-106	-46	-27
Consolidated Net Income / (Loss)	-106	-46	-27
Depreciation Expense	6.39	1.01	0.94
Amortization Expense	-0.89	0.00	-
Non-Cash Adjustments To Reconcile Net Income	38	8.74	7.79
Changes in Operating Assets and Liabilities, net	-7.19	2.77	-0.68
Net Cash From Investing Activities	-22	-17	-37
Net Cash From Continuing Investing Activities	-22	-17	-37
Purchase of Property, Plant & Equipment	0.00	-0.30	-0.09
Acquisitions	-6.00	-30	-14
Purchase of Investments	-41	-46	-24
Sale and/or Maturity of Investments	25	59	1.33
Net Cash From Financing Activities	82	28	8.35
Net Cash From Continuing Financing Activities	82	28	8.35
Repayment of Debt	-45	-18	-0.02
Repurchase of Common Equity	0.00	-3.45	-4.72
Issuance of Debt	59	42	13
Issuance of Common Equity	66	6.32	0.32
Other Financing Activities, net	2.34	0.69	-0.03
Effect of Exchange Rate Changes	0.45	-	0.20
Cash Interest Paid	5.26	0.46	0.32

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-20	15	-3.59	-0.20	-0.22	-23	26	-25	-4.59	-6.72
Net Cash From Operating Activities	-16	-18	-19	-16	-16	-4.63	-8.70	-4.05	-4.46	-6.60
Net Cash From Continuing Operating Activities	-16	-18	-19	-16	-16	-4.63	-8.70	-4.05	-4.46	-6.60
Net Income / (Loss) Continuing Operations	-36	-33	-20	-17	-20	-10	-2.57	-13	5.75	-6.62
Consolidated Net Income / (Loss)	-36	-33	-20	-17	-20	-10	-2.57	-13	5.75	-6.62
Depreciation Expense	1.65	1.62	1.56	1.56	0.79	0.06	0.08	0.08	0.30	0.40
Non-Cash Adjustments To Reconcile Net Income	24	11	2.37	0.06	4.79	-1.31	1.66	3.60	-15	1.90
Changes in Operating Assets and Liabilities, net	-5.37	2.46	-3.12	-1.16	-1.85	6.99	-7.87	5.50	3.99	-2.28
Net Cash From Investing Activities	-5.47	-31	-0.13	15	11	-44	34	-18	-0.06	0.27
Net Cash From Continuing Investing Activities	-5.47	-31	-0.13	15	11	-44	34	-18	-0.06	0.27
Purchase of Investments	0.33	-41	-	-	25	-54	-	-	-0.03	-
Sale and/or Maturity of Investments	0.20	10	-	15	16	9.50	52	-18	-	0.30
Net Cash From Financing Activities	0.80	65	15	1.22	5.00	26	0.95	-3.75	-0.26	-0.41
Net Cash From Continuing Financing Activities	0.80	65	15	1.22	5.00	26	0.95	-3.75	-0.26	-0.41
Issuance of Common Equity	-0.89	65	0.48	1.22	6.11	0.05	0.17	0.00	-	-
Other Financing Activities, net	1.68	-	0.65	0.00	-	-0.00	1.11	-0.42	-0.63	-0.42
Cash Interest Paid	1.59	1.53	2.00	0.14	-	0.20	0.19	0.07	0.16	0.12

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	178	172	115
Total Current Assets	86	87	93
Cash & Equivalents	34	43	65
Short-Term Investments	36	25	17
Accounts Receivable	11	17	8.30
Inventories, net	1.97	0.00	-
Prepaid Expenses	4.05	1.82	1.69
Plant, Property, & Equipment, net	0.36	0.74	0.79
Total Noncurrent Assets	92	85	22
Long-Term Investments	6.01	0.00	20
Goodwill	4.70	4.70	0.00
Intangible Assets	69	69	0.00
Other Noncurrent Operating Assets	12	11	1.71
Total Liabilities & Shareholders' Equity	178	172	115
Total Liabilities	138	110	40
Total Current Liabilities	34	74	12
Short-Term Debt	0.00	38	0.00
Accounts Payable	25	28	6.17
Other Current Liabilities	8.61	7.62	5.85
Total Noncurrent Liabilities	104	37	28
Long-Term Debt	60	5.07	13
Noncurrent Deferred Revenue	14	0.00	-
Other Noncurrent Operating Liabilities	30	32	15
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	40	62	75
Total Preferred & Common Equity	40	62	75
Preferred Stock	0.00	0.00	0.00
Total Common Equity	40	62	75
Common Stock	555	473	436
Retained Earnings	-505	-400	-354
Treasury Stock	-11	-11	-7.54
Accumulated Other Comprehensive Income / (Loss)	0.63	-0.04	0.11

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	192	144	151	139	106	107	120
Total Current Assets	99	61	63	137	103	104	85
Cash & Equivalents	54	39	43	43	66	40	70
Short-Term Investments	35	10.00	9.87	40	21	55	5.83
Accounts Receivable	7.79	8.95	8.31	9.93	14	7.82	6.58
Prepaid Expenses	2.28	2.69	1.87	1.66	2.02	1.17	2.66
Plant, Property, & Equipment, net	0.61	0.68	0.70	0.64	0.69	0.74	0.85
Total Noncurrent Assets	92	83	88	1.33	1.40	1.57	34
Long-Term Investments	6.11	-	-	0.00	0.00	0.00	31
Goodwill	4.70	4.70	4.70	-	-	-	-
Intangible Assets	71	66	68	-	-	-	-
Other Noncurrent Operating Assets	10	12	15	1.33	1.40	1.57	2.10
Total Liabilities & Shareholders' Equity	192	144	151	139	106	107	120
Total Liabilities	122	112	102	72	37	35	26
Total Current Liabilities	34	30	30	22	18	16	8.43
Short-Term Debt	0.00	0.00	0.00	-	-	-	-
Accounts Payable	24	20	23	13	11	10	4.28
Other Current Liabilities	10	10.00	7.12	8.63	7.74	5.52	4.15
Total Noncurrent Liabilities	87	81	73	50	19	20	17
Long-Term Debt	59	58	43	44	13	13	13
Other Noncurrent Operating Liabilities	28	23	30	5.92	6.06	6.66	4.53
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	70	32	49	67	68	71	94
Total Preferred & Common Equity	70	32	49	67	68	71	94
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	70	32	49	67	68	71	94
Common Stock	550	479	476	418	405	403	401
Retained Earnings	-470	-436	-416	-339	-325	-320	-300
Treasury Stock	-11	-11	-11	-11	-11	-11	-7.54
Accumulated Other Comprehensive Income / (Loss)	-0.12	0.42	0.14	-0.22	-0.23	-0.06	0.20

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-14.02%	170.26%	-64.53%
EBITDA Growth	-65.27%	-77.83%	-433.40%
EBIT Growth	-73.08%	-75.42%	-463.27%
NOPAT Growth	-75.40%	-16.54%	-650.72%
Net Income Growth	-129.13%	-72.00%	-212.94%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-107.74%	-79.17%	-279.30%
Free Cash Flow Firm Growth	44.91%	-457.68%	-512.15%
Invested Capital Growth	-35.86%	347.16%	-2,196.46%
Revenue Q/Q Growth	-3.58%	65.80%	-5.22%
EBITDA Q/Q Growth	1.50%	-105.40%	24.62%
EBIT Q/Q Growth	1.44%	-105.15%	23.49%
NOPAT Q/Q Growth	-0.30%	-13.35%	-17.93%
Net Income Q/Q Growth	-17.67%	-125.65%	24.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-0.13%	-53.56%	-23.93%
Free Cash Flow Firm Q/Q Growth	27.76%	-45.92%	36.06%
Invested Capital Q/Q Growth	-28.71%	32.15%	-1,864.08%
Profitability Metrics	-	-	-
Gross Margin	68.59%	92.09%	97.82%
EBITDA Margin	-336.55%	-175.10%	-266.11%
Operating Margin	-368.47%	-180.63%	-418.91%
EBIT Margin	-359.83%	-178.76%	-275.40%
Profit (Net Income) Margin	-446.85%	-167.69%	-263.48%
Tax Burden Percent	117.05%	100.00%	99.88%
Interest Burden Percent	106.09%	93.81%	95.79%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-201.14%	-316.15%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	16.61%	-296.46%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-6.70%	248.92%	0.00%
Return on Equity (ROE)	-207.84%	-67.23%	-26.48%
Cash Return on Invested Capital (CROIC)	-157.45%	-234.58%	0.00%
Operating Return on Assets (OROA)	-48.49%	-34.13%	-22.54%
Return on Assets (ROA)	-60.21%	-32.02%	-21.57%
Return on Common Equity (ROCE)	-207.84%	-67.23%	-26.48%
Return on Equity Simple (ROE_SIMPLE)	-266.00%	-74.44%	-35.64%
Net Operating Profit after Tax (NOPAT)	-61	-35	-30
NOPAT Margin	-257.93%	-126.44%	-293.23%
Net Nonoperating Expense Percent (NNEP)	-217.75%	-19.69%	2.78%
Return On Investment Capital (ROIC_SIMPLE)	-61.41%	-33.19%	-
Cost of Revenue to Revenue	31.41%	7.91%	2.18%
SG&A Expenses to Revenue	232.37%	124.96%	148.00%
R&D to Revenue	178.28%	144.95%	368.72%
Operating Expenses to Revenue	437.06%	272.72%	516.72%
Earnings before Interest and Taxes (EBIT)	-85	-49	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-79	-48	-27
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	11.22	3.83	2.11
Price to Tangible Book Value (P/TBV)	0.00	0.00	2.11
Price to Revenue (P/Rev)	18.85	8.64	15.59
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	18.14	5.75	0.00
Enterprise Value to Revenue (EV/Rev)	18.18	7.73	6.72
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.50	0.69	0.17
Long-Term Debt to Equity	1.50	0.08	0.17
Financial Leverage	-0.40	-0.84	-1.08
Leverage Ratio	3.45	2.10	1.23
Compound Leverage Factor	3.66	1.97	1.18
Debt to Total Capital	60.00%	40.87%	14.56%
Short-Term Debt to Total Capital	0.00%	36.03%	0.00%
Long-Term Debt to Total Capital	60.00%	4.84%	14.56%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	40.00%	59.13%	85.44%
Debt to EBITDA	-0.75	-0.89	-0.47
Net Debt to EBITDA	0.20	0.52	3.33
Long-Term Debt to EBITDA	-0.75	-0.11	-0.47
Debt to NOPAT	-0.98	-1.23	-0.43
Net Debt to NOPAT	0.26	0.72	3.02
Long-Term Debt to NOPAT	-0.98	-0.15	-0.43
Altman Z-Score	-3.13	-2.65	-1.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.53	1.18	7.72
Quick Ratio	2.35	1.15	7.58
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-48	-87	-16
Operating Cash Flow to CapEx	0.00%	-11,329.39%	-20,125.81%
Free Cash Flow to Firm to Interest Expense	-9.21	0.00	0.00
Operating Cash Flow to Interest Expense	-13.46	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-13.46	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.13	0.19	0.08
Accounts Receivable Turnover	1.69	2.14	2.07
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	43.25	35.90	12.11
Accounts Payable Turnover	0.28	0.13	0.05
Days Sales Outstanding (DSO)	215.53	170.64	176.50
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,325.23	2,903.54	7,568.82
Cash Conversion Cycle (CCC)	-1,109.70	-2,732.90	-7,392.32
Capital & Investment Metrics	-	-	-
Invested Capital	24	37	-15
Invested Capital Turnover	0.78	2.50	-1.30
Increase / (Decrease) in Invested Capital	-13	52	-14
Enterprise Value (EV)	429	212	68
Market Capitalization	445	237	158
Book Value per Share	$0.74	$1.71	$2.18
Tangible Book Value per Share	($0.64)	($0.33)	$2.18
Total Capital	99	105	88
Total Debt	60	43	13
Total Long-Term Debt	60	5.07	13
Net Debt	-16	-25	-90
Capital Expenditures (CapEx)	0.00	0.30	0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-17	-2.04
Debt-free Net Working Capital (DFNWC)	52	51	81
Net Working Capital (NWC)	52	13	81
Net Nonoperating Expense (NNE)	45	11	-3.02
Net Nonoperating Obligations (NNO)	-16	-25	-90
Total Depreciation and Amortization (D&A)	5.50	1.01	0.94
Debt-free, Cash-free Net Working Capital to Revenue	-74.26%	-61.25%	-20.04%
Debt-free Net Working Capital to Revenue	220.07%	185.42%	795.31%
Net Working Capital to Revenue	220.07%	48.13%	795.31%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.28)	($1.30)	($1.20)
Adjusted Weighted Average Basic Shares Outstanding	46.25M	35.45M	34.49M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	54.12M	43.43M	34.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.12M	43.43M	34.54M
Normalized Net Operating Profit after Tax (NOPAT)	-61	-35	-30
Normalized NOPAT Margin	-257.93%	-126.44%	-293.23%
Pre Tax Income Margin	-381.76%	-167.69%	-263.80%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-16.42	0.00	0.00
NOPAT to Interest Expense	-11.77	0.00	0.00
EBIT Less CapEx to Interest Expense	-16.42	0.00	0.00
NOPAT Less CapEx to Interest Expense	-11.77	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-7.49%	-17.64%

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.79%	27.63%	-47.47%	7.84%	538.97%	0.73%	551.54%	-19.90%	-21.69%	46.26%
EBITDA Growth	11.34%	-163.87%	-319.18%	-8.67%	-403.37%	-81.25%	84.24%	-640.21%	325.55%	-247.67%
EBIT Growth	6.43%	-176.44%	-350.04%	-19.08%	-432.54%	-71.47%	84.04%	-619.80%	309.55%	-256.77%
NOPAT Growth	-1.71%	-77.73%	-280.60%	-59.66%	-28.17%	-131.87%	74.76%	-590.21%	-316.10%	-198.20%
Net Income Growth	-79.67%	-220.49%	-674.39%	-25.76%	-445.95%	-56.70%	89.30%	-609.07%	312.73%	-276.12%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-0.57%	-291.98%	-119.54%	-299.63%	-262.12%	29.86%	-112.09%	-13.85%	-426.18%	-141.69%
Free Cash Flow Firm Growth	103.90%	38.15%	-9,182.88%	-1,584.23%	-1,140.65%	-982.07%	95.79%	-18.89%	265.06%	-27.05%
Invested Capital Growth	-35.86%	18.89%	774.15%	456.55%	347.16%	3,773.42%	-148.51%	-565.65%	-2,196.46%	-424.79%
Revenue Q/Q Growth	225.93%	-16.95%	29.90%	-73.49%	346.29%	-65.82%	166.69%	57.07%	-29.65%	121.08%
EBITDA Q/Q Growth	45.78%	-84.43%	-7.37%	-2.99%	-61.37%	-192.99%	72.17%	-330.52%	196.41%	74.52%
EBIT Q/Q Growth	43.37%	-77.42%	-6.69%	-7.79%	-67.31%	-188.83%	71.77%	-343.77%	186.27%	73.12%
NOPAT Q/Q Growth	43.54%	-14.76%	-16.15%	-35.16%	1.35%	-145.75%	51.27%	-8.50%	-78.47%	73.25%
Net Income Q/Q Growth	-7.57%	-66.75%	-19.87%	-2.52%	-91.88%	-302.91%	80.53%	-329.86%	186.91%	72.48%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	10.42%	5.07%	-18.21%	-0.04%	-249.14%	46.83%	-115.18%	9.35%	32.37%	-60.77%
Free Cash Flow Firm Q/Q Growth	110.00%	62.11%	0.06%	-3.16%	-58.32%	-5,586.88%	-115.98%	-27.67%	264.62%	77.90%
Invested Capital Q/Q Growth	-28.71%	-20.11%	6.26%	5.98%	32.15%	552.99%	43.80%	26.54%	-1,864.08%	69.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.66%	37.67%	19.69%	94.89%	90.50%	95.03%	92.01%	96.06%	98.91%	95.09%
EBITDA Margin	-136.62%	-821.24%	-369.81%	-447.42%	-143.63%	-397.24%	-46.34%	-443.99%	302.52%	-220.77%
Operating Margin	-128.01%	-739.00%	-534.84%	-598.13%	-117.31%	-530.71%	-73.81%	-404.00%	-460.58%	-230.55%
EBIT Margin	-150.30%	-865.01%	-404.92%	-493.02%	-149.72%	-399.38%	-47.26%	-446.47%	287.69%	-234.62%
Profit (Net Income) Margin	-296.76%	-899.19%	-447.85%	-485.31%	-153.96%	-358.10%	-30.38%	-416.15%	284.37%	-230.20%
Tax Burden Percent	175.47%	100.00%	100.35%	99.58%	100.00%	101.74%	97.20%	99.23%	88.89%	99.50%
Interest Burden Percent	112.52%	103.95%	110.21%	98.85%	102.83%	88.13%	66.13%	93.94%	111.21%	98.61%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.11%	0.00%
Return on Invested Capital (ROIC)	-69.88%	-414.59%	-501.28%	-824.79%	-205.33%	-453.13%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	51.90%	-377.52%	-491.31%	-819.84%	-189.19%	-453.71%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-20.94%	209.42%	319.14%	627.99%	158.85%	377.30%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-90.82%	-205.18%	-182.13%	-196.80%	-46.48%	-75.83%	-19.86%	-39.53%	-26.48%	-31.24%
Cash Return on Invested Capital (CROIC)	-157.45%	-215.99%	-240.86%	-230.56%	-234.58%	-212.44%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-20.25%	-128.18%	-76.76%	-105.95%	-28.59%	-51.17%	-6.80%	-36.03%	23.55%	-19.59%
Return on Assets (ROA)	-39.99%	-133.24%	-84.90%	-104.30%	-29.39%	-45.88%	-4.37%	-33.58%	23.28%	-19.23%
Return on Common Equity (ROCE)	-90.82%	-205.18%	-182.13%	-196.80%	-46.48%	-75.83%	-19.86%	-39.53%	-26.48%	-31.24%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-128.51%	-205.70%	-101.30%	0.00%	-30.25%	-24.32%	-53.39%	0.00%	-37.56%
Net Operating Profit after Tax (NOPAT)	-11	-19	-17	-14	-11	-11	-4.38	-8.98	-8.28	-4.64
NOPAT Margin	-89.61%	-517.30%	-374.39%	-418.69%	-82.12%	-371.50%	-51.67%	-282.80%	-409.39%	-161.38%
Net Nonoperating Expense Percent (NNEP)	-121.78%	-37.07%	-9.97%	-4.96%	-16.14%	0.58%	2.05%	-4.20%	12.88%	-1.75%
Return On Investment Capital (ROIC_SIMPLE)	-10.88%	-	-	-	-10.14%	-	-	-	-	-
Cost of Revenue to Revenue	11.34%	62.33%	80.31%	5.11%	9.50%	4.97%	7.99%	3.94%	1.09%	4.91%
SG&A Expenses to Revenue	133.90%	438.65%	283.30%	289.96%	113.44%	200.97%	78.06%	227.55%	236.00%	138.27%
R&D to Revenue	69.35%	296.21%	236.48%	358.45%	88.40%	424.77%	87.76%	272.51%	323.49%	187.37%
Operating Expenses to Revenue	216.67%	776.67%	554.53%	693.02%	207.82%	625.73%	165.82%	500.06%	559.50%	325.64%
Earnings before Interest and Taxes (EBIT)	-18	-32	-18	-17	-19	-12	-4.00	-14	5.82	-6.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-30	-16	-15	-19	-12	-3.93	-14	6.12	-6.35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.22	5.23	6.31	4.30	3.83	2.42	2.52	2.66	2.11	2.29
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	2.42	2.52	2.66	2.11	2.29
Price to Revenue (P/Rev)	18.85	14.91	8.66	7.58	8.64	9.87	10.45	20.27	15.59	20.08
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	18.14	9.90	5.15	5.12	5.75	4.44	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	18.18	13.42	9.04	7.23	7.73	7.49	5.93	11.48	6.72	11.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.50	0.84	1.80	0.88	0.69	0.65	0.19	0.18	0.17	0.14
Long-Term Debt to Equity	1.50	0.84	1.80	0.88	0.08	0.65	0.19	0.18	0.17	0.14
Financial Leverage	-0.40	-0.55	-0.65	-0.77	-0.84	-0.83	-1.05	-1.04	-1.08	-1.00
Leverage Ratio	3.45	2.41	2.48	2.15	2.10	1.60	1.37	1.20	1.23	1.14
Compound Leverage Factor	3.88	2.50	2.73	2.12	2.16	1.41	0.91	1.13	1.37	1.12
Debt to Total Capital	60.00%	45.78%	64.23%	46.83%	40.87%	39.40%	15.65%	15.32%	14.56%	12.01%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	36.03%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	60.00%	45.78%	64.23%	46.83%	4.84%	39.40%	15.65%	15.32%	14.56%	12.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	40.00%	54.22%	35.77%	53.17%	59.13%	60.60%	84.35%	84.68%	85.44%	87.99%
Debt to EBITDA	-0.75	-0.73	-0.94	-0.87	-0.89	-1.87	-0.70	-0.33	-0.47	-0.36
Net Debt to EBITDA	0.20	0.45	-0.15	0.20	0.52	1.69	4.09	2.10	3.33	2.64
Long-Term Debt to EBITDA	-0.75	-0.73	-0.94	-0.87	-0.11	-1.87	-0.70	-0.33	-0.47	-0.36
Debt to NOPAT	-0.98	-0.97	-1.11	-1.07	-1.23	-1.43	-0.52	-0.34	-0.43	-0.51
Net Debt to NOPAT	0.26	0.60	-0.17	0.24	0.72	1.29	3.05	2.20	3.02	3.74
Long-Term Debt to NOPAT	-0.98	-0.97	-1.11	-1.07	-0.15	-1.43	-0.52	-0.34	-0.43	-0.51
Altman Z-Score	-1.90	-1.65	-3.13	-2.55	-2.08	-1.21	-0.52	-0.32	-0.84	2.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.53	2.88	2.00	2.10	1.18	6.31	5.67	6.68	7.72	10.10
Quick Ratio	2.35	2.82	1.91	2.04	1.15	6.23	5.56	6.60	7.58	9.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	2.44	-24	-64	-64	-62	-39	-0.69	4.34	6.00	-3.64
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	-22,441.67%	-2,690.70%	-37,843.48%	-13,948.28%	-13,123.53%	-23,564.29%
Free Cash Flow to Firm to Interest Expense	1.08	-19.31	-34.98	0.00	-113.92	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-7.17	-14.36	-10.39	0.00	-29.49	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-7.17	-14.36	-10.39	0.00	-29.62	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.15	0.19	0.21	0.19	0.13	0.14	0.08	0.08	0.08
Accounts Receivable Turnover	1.69	2.76	2.06	3.44	2.14	2.01	1.96	1.68	2.07	2.61
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	43.25	39.21	34.66	38.51	35.90	22.17	20.77	11.87	12.11	12.03
Accounts Payable Turnover	0.28	0.43	0.38	0.18	0.13	0.11	0.14	0.05	0.05	0.40
Days Sales Outstanding (DSO)	215.53	132.03	177.04	106.21	170.64	181.92	185.93	216.97	176.50	139.62
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,325.23	851.15	959.19	2,003.72	2,903.54	3,272.75	2,668.47	6,826.25	7,568.82	922.50
Cash Conversion Cycle (CCC)	-1,109.70	-719.12	-782.15	-1,897.51	-2,732.90	-3,090.83	-2,482.54	-6,609.29	-7,392.32	-782.88
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	24	33	42	39	37	28	-6.16	-11	-15	-0.76
Invested Capital Turnover	0.78	0.80	1.34	1.97	2.50	1.22	-3.83	-2.18	-1.30	-40.76
Increase / (Decrease) in Invested Capital	-13	5.28	48	50	52	29	-3.68	-13	-14	-0.99
Enterprise Value (EV)	429	329	214	200	212	124	98	108	68	121
Market Capitalization	445	365	205	210	237	164	173	190	158	215
Book Value per Share	$0.74	$1.33	$0.78	$1.35	$1.71	$1.99	$2.02	$2.07	$2.18	$2.72
Tangible Book Value per Share	($0.64)	($0.11)	($0.92)	($0.65)	($0.33)	$1.99	$2.02	$2.07	$2.18	$2.72
Total Capital	99	129	91	92	105	111	81	84	88	107
Total Debt	60	59	58	43	43	44	13	13	13	13
Total Long-Term Debt	60	59	58	43	5.07	44	13	13	13	13
Net Debt	-16	-37	9.07	-9.72	-25	-40	-75	-82	-90	-95
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.07	0.17	0.02	0.03	0.03	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-24	-19	-20	-17	32	-2.20	-6.62	-2.04	0.81
Debt-free Net Working Capital (DFNWC)	52	65	30	33	51	115	85	89	81	77
Net Working Capital (NWC)	52	65	30	33	13	115	85	89	81	77
Net Nonoperating Expense (NNE)	25	14	3.27	2.28	9.28	-0.39	-1.80	4.24	-14	1.98
Net Nonoperating Obligations (NNO)	-16	-37	9.07	-9.72	-25	-40	-75	-82	-90	-95
Total Depreciation and Amortization (D&A)	1.65	1.62	1.56	1.56	0.79	0.06	0.08	0.08	0.30	0.40
Debt-free, Cash-free Net Working Capital to Revenue	-74.26%	-99.70%	-79.43%	-71.22%	-61.25%	192.43%	-13.28%	-70.64%	-20.04%	7.56%
Debt-free Net Working Capital to Revenue	220.07%	265.27%	128.51%	119.02%	185.42%	696.12%	514.90%	946.05%	795.31%	715.44%
Net Working Capital to Revenue	220.07%	265.27%	128.51%	119.02%	48.13%	696.12%	514.90%	946.05%	795.31%	715.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.71)	($0.69)	($0.48)	($0.40)	($0.54)	($0.40)	($0.15)	($0.34)	$0.16	($0.19)
Adjusted Weighted Average Basic Shares Outstanding	46.25M	47.81M	41.90M	41.78M	35.45M	34.72M	33.90M	34.47M	34.49M	34.49M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	54.12M	53.38M	52.62M	41.85M	43.43M	36.22M	33.93M	33.88M	34.54M	34.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.12M	53.38M	52.62M	41.85M	43.43M	36.22M	33.93M	33.88M	34.54M	34.50M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-19	-17	-14	-11	-11	-4.38	-8.98	-8.28	-4.64
Normalized NOPAT Margin	-89.61%	-517.30%	-374.39%	-418.69%	-82.12%	-371.50%	-51.67%	-282.80%	-409.39%	-161.38%
Pre Tax Income Margin	-169.13%	-899.19%	-446.28%	-487.36%	-153.96%	-351.99%	-31.25%	-419.40%	319.93%	-231.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.98	-25.31	-9.79	0.00	-35.30	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-4.76	-15.13	-9.05	0.00	-19.36	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-7.98	-25.31	-9.79	0.00	-35.43	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-4.76	-15.13	-9.05	0.00	-19.49	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-7.49%	-16.56%	-20.29%	-9.04%	-17.64%	-13.71%

Frequently Asked Questions About Zevra Therapeutics' Financials

When does Zevra Therapeutics's financial year end?

According to the most recent income statement we have on file, Zevra Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Zevra Therapeutics' net income changed over the last 2 years?

Zevra Therapeutics' net income appears to be on an upward trend, with a most recent value of -$105.51 million in 2024, rising from -$26.77 million in 2022. The previous period was -$46.05 million in 2023. Find out what analysts predict for Zevra Therapeutics in the coming months.

What is Zevra Therapeutics's operating income?

Zevra Therapeutics's total operating income in 2024 was -$87.00 million, based on the following breakdown:

Total Gross Profit: $16.20 million
Total Operating Expenses: $103.20 million

How has Zevra Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Zevra Therapeutics' total revenue changed from $10.16 million in 2022 to $23.61 million in 2024, a change of 132.4%.

How much debt does Zevra Therapeutics have?

Zevra Therapeutics' total liabilities were at $138.46 million at the end of 2024, a 25.3% increase from 2023, and a 244.3% increase since 2022.

How much cash does Zevra Therapeutics have?

In the past 2 years, Zevra Therapeutics' cash and equivalents has ranged from $33.79 million in 2024 to $65.47 million in 2022, and is currently $33.79 million as of their latest financial filing in 2024.

How has Zevra Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Zevra Therapeutics' book value per share changed from 2.18 in 2022 to 0.74 in 2024, a change of -65.9%.

Related Companies

This page (NASDAQ:ZVRA) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Financials

Frequently Asked Questions About Zevra Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Financials

Annual Income Statements for Zevra Therapeutics

Quarterly Income Statements for Zevra Therapeutics

Annual Cash Flow Statements for Zevra Therapeutics

Quarterly Cash Flow Statements for Zevra Therapeutics

Annual Balance Sheets for Zevra Therapeutics

Quarterly Balance Sheets for Zevra Therapeutics

Annual Metrics And Ratios for Zevra Therapeutics

Quarterly Metrics And Ratios for Zevra Therapeutics

Frequently Asked Questions About Zevra Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools